The National Institute of Allergy and Infectious Diseases (“NIAID”) recently published Broad Agency Announcement (‘BAA”) No. HHS-NIH-NIAID-BAA2023-1, which provides funding opportunities for the advancement of promising candidate vaccines, therapeutics, and diagnostics for Biodefense, Emerging Infectious Diseases, and Pandemic Preparedness.
Four Areas for NIAID Funding
1. Research Area 001 – Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
The goal of Research Area 001 is to protect human health and well-being by advancing specific vaccine candidates that utilize technology platforms that ideally elicit a rapid onset of immunity following a single dose, provide a durable response, and are readily adaptable to multiple emerging pathogens.
Proposals Due Date and Time – April 11, 2023, 3:00 PM Eastern Time
2. Research Area 002 – Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases
The objective of Research Area 002 is the development of new therapeutics for diseases caused by NIAID Emerging Infectious Diseases/Pathogens including Category A, B and C priority pathogens and certain bacterial and fungal pathogens identified in the 2019 CDC Antibiotic Resistance Threats Report.
Proposals Due Date and Time – April 11, 2023, 3:00 PM Eastern Time
3. Research Area 003 – Antiviral Program for Pandemics (APP): Development of Antivirals for RNA Viral Families of Pandemic Potential
The Antiviral Program for Pandemics (APP; https://www.niaid.nih.gov/research/antivirals) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.
Proposals Due Date and Time – March 13, 2023, 3:00 PM Eastern Time
4. Research Area 004 – Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections, and Emerging Infectious Diseases
NIAID is interested in supporting the development of promising diagnostics technologies in three areas for the detection of signatures from biothreat pathogens and toxins, as well as pathogens causing emerging, reemerging, antimicrobial-resistant infectious diseases, and for future pandemic preparedness.
- Next-generation Nucleic Acid Sequencing on Portable Systems
- Rapid Protein Detection
- Bacterial Identification and Phenotypic Antimicrobial Resistance Characterization.
Proposals Due Date and Time – April 11, 2023, 3:00 PM Eastern Time
Funding for Vaccine Development Overview
If you are developing (or are in preclinical development of) a product that you think might fall into one of these categories, EverGlade can help you make that determination and pursue a successful contract. EverGlade Consulting is a national consulting firm helping clients navigate the federal landscape. We work with technology-driven companies whose focus is to secure non-dilutive funding through the federal government. We offer services ranging from opportunity identification and proposal support through the implementation of systems to comply with federal regulations at agencies including BARDA, ASPR, NIH, DTRA, JPEO, and DARPA.
For additional information about EverGlade’s recent success, visit:
EverGlade Consulting Helps Land Up To 1 Billion in Barda Funding
EverGlade Consulting Assists Detect, Inc. with Securing $22m in Federal Funding for the
Development of a Next Generation Molecular Test for COVID-19 and Flu
EverGlade Consulting Assists United Safety Technology, Inc. in Securing $97 Million DOD Award